Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer cells. The Saudi Food and Drug Authority has become the first regulatory body globally to grant conditional approval for Anktiva in advanced non-small cell lung cancer and high-risk bladder cancer, offering a new treatment option for patients with limited alternatives.
Click here to
Read more
